Pharmacokinetic interactions between herbal medicines and prescribed drugs: Focus on drug metabolic enzymes and transporters

Current Drug Metabolism

Volumn 15, Issue 8, 2014, Pages 791-807

  Meng, Qiang ^a   Liu, Kexin ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

CYPs; Herb drug interactions; Herbal medicines; P gp; Pharmacokinetics; Transporters

Indexed keywords

ANTINEOPLASTIC AGENT; BEXAROTENE; BORTEZOMIB; BOSUTINIB; CARBAMAZEPINE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DASATINIB; DOCETAXEL; ERLOTINIB; ERYTHROMYCIN; EVEROLIMUS; GEFITINIB; IFOSFAMIDE; IMATINIB; IRINOTECAN; ITRACONAZOLE; KETOCONAZOLE; LAPATINIB; MOTESANIB; NILOTINIB; PACLITAXEL; PHENYTOIN; RIFAMPICIN; RITONAVIR; RUXOLITINIB; SUNITINIB; THIOTEPA; UNINDEXED DRUG; CARRIER PROTEIN; ENZYME; PLANT MEDICINAL PRODUCT; PRESCRIPTION DRUG;

AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CANCER THERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; HUMAN; RISK BENEFIT ANALYSIS; RISK REDUCTION; ANIMAL; CHEMISTRY; DRUG EFFECTS; HALF LIFE TIME; HERB DRUG INTERACTION; MEDICINAL PLANT; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL TRANSPORT; ENZYMES; HALF-LIFE; HERB-DRUG INTERACTIONS; HUMANS; MEMBRANE TRANSPORT PROTEINS; PLANT PREPARATIONS; PLANTS, MEDICINAL; PRESCRIPTION DRUGS;

EID: 84930902643     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200216666150223152348     Document Type: Article

References (200)

1. Chen, X.W.; Serag, E.S.; Sneed, K.B.; Liang, J.; Chew, H.; Pan, S.Y.; Zhou, S.F. Clinical herbal interactions with conventional drugs: from molecules to maladies. Curr. Med. Chem., 2011, 18(31), 4836-4850.
2. Chen, X.W.; Sneed, K.B.; Pan, S.Y.; Cao, C.; Kanwar, J.R.; Chew, H.; Zhou, S.F. Herb-drug interactions and mechanistic and clinical considerations. Curr. Drug Metab., 2012, 13(5), 640-651.
3. Gunther, S.; Patterson, R.E.; Kristal, A.R.; Stratton, K.L.; White, E. Demographic and health-related correlates of herbal and specialty supplement use. J. Am. Diet Assoc., 2004, 104(1), 27-34.
4. Kaufman, D.W.; Kelly, J.P.; Rosenberg, L.; Anderson, T.E.; Mitchell, A. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA, 2002, 287(3), 337-344.
5. Butterweck, V.; Derendorf, H. Potential of pharmacokinetic profiling for detecting herbal interactions with drugs. Clin. Pharmacokinet., 2008, 47 (6), 383-397.
6. Tarirai, C.; Viljoen, A.M.; Hamman, J.H. Herb-drug pharmacokinetic interactions reviewed. Expert Opin. Drug Metab. Toxicol., 2010, 6 (12), 1515-1538.
7. Mukherjee, P.K.; Ponnusankar, S.; Pandit, S.; Hazam, P.K.; Ahmmed, M.; Mukherjee, K. Botanicals as medicinal food and their effects on drug metabolizing enzymes. Food Chem. Toxicol., 2011, 49(12), 3142-3153.
8. Hu, Z.P.; Yang, X.X.; Chen, X.; Cao, J.; Chan, E.; Duan, W.; Huang, M.; Yu, X.Q.; Wen, J.Y.; Zhou, S.F. A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort. Curr. Drug Metab., 2007, 8(2), 157-171.
9. Smith, P.; Bullock, J.M.; Booker, B.M.; Haas, C.E.; Berenson, C.S.; Jusko, W.J. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy, 2004, 24(11), 1508-1514.
10. Gödtel-Armbrust, U.; Metzger, A.; Kroll, U.; Kelber, O.; Wojnowski, L. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort. Naunyn Schmiedebergs Arch. Pharmacol., 2007, 375(6), 377-382.
11. Gurley, B.J. Pharmacokinetic herb-drug interactions (part 1): origins, mechanisms, and the impact of botanical dietary supplements. Planta. Med., 2012, 78(13), 1478-1489.
12. Dasgupta, A. Herbal supplements and therapeutic drug monitoring: focus on digoxin immunoassays and interactions with St. John's wort. Ther. Drug Monit., 2008, 30(2), 212-217.
13. Reif, S.; Nicolson, M.C.; Bisset, D.; Reid, M.; Kloft, C.; Jaehde, U.; McLeod, H.L. Effect of grapefruit juice intake on etoposide bioavailability. Eur. J. Clin. Pharmacol., 2002, 58(7), 491-494.
14. Li, X.; Hu, J.; Wang, B.; Sheng, L.; Liu, Z.; Yang, S.; Li, Y. Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: herb-drug interactions mediated via P-gp. Toxicol. Appl. Pharmacol., 2014, 275(2), 163-175.
15. Li, Y.; Wang, Q.; Yao, X.; Li, Y. Induction of CYP3A4 and MDR1 gene expression by baicalin, baicalein, chlorogenic acid, and ginsenoside Rf through constitutive androstane receptor- And pregnane X receptor-mediated pathways. Eur. J. Pharmacol., 2010, 640(1-3), 46-54.
16. Yale, S.H.; Glurich, I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J. Altern. Complement. Med., 2005, 11, 433-439.
17. Fang, Z.Z.; Cao, Y.F.; Hu, C.M.; Hong, M.; Sun, X.Y.; Ge, G.B.; Liu, Y.; Zhang, Y.Y.; Yang, L.; Sun, H.Z. Structure-inhibition relationship of ginsenosides towards UDP-glucuronosyltransferases (UGTs). Toxicol. Appl. Pharmacol., 2013, 267(2), 149-154.
18. Giacomotto, J.; Ségalat, L. High-throughput screening and small animal models, where are we? Br. J. Pharmacol., 2010, 160(2), 204-216.
19. Broderick, D.; Clarke, M.; Stassen, L. Midazolam and drug-drug interactions in dental conscious sedation. J. Ir. Dent. Assoc., 2014, 60(1), 38-43.
20. Wang, X.; Han, A.; Wen, C.; Chen, M.; Chen, X.; Yang, X.; Ma, J.; Lin, G. The effects of H2S on the activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in vivo in rat. Int. J. Mol. Sci., 2013, 14(12), 24055-24063.
21. Kaur, S.; Chhabra, R.; Nehru, B. Ginkgo biloba extract attenuates hippocampal neuronal loss and cognitive dysfunction resulting from trimethyltin in mice. Phytomedicine, 2013, 20(2), 178-186.
22. He, Y.T.; Xing, S.S.; Gao, L.; Wang, J.; Xing, Q.C.; Zhang, W. Ginkgo biloba attenuates oxidative DNA damage of human umbilical vein endothelial cells induced by intermittent high glucose. Pharmazie, 2014, 69(3), 203-207.
23. Li, L.; Zhao, Y.; Du, F.; Yang, J.; Xu, F.; Niu, W.; Ren, Y.; Li, C. Intestinal absorption and presystemic elimination of various chemical constituents present in GBE50 extract, a standardized extract of Ginkgo biloba leaves. Curr. Drug Metab., 2012, 13(5), 494-509.
24. Zou, L.; Harkey, M.R.; Henderson, G.L. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci., 2002, 71(13), 1579-1589.
25. Hellum, B.H.; Hu, Z.; Nilsen, O.G. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin. Pharmacol Toxicol., 2007, 100(1), 23-30.
26. Gaudineau, C.; Beckerman, R.; Welbourn, S.; Auclair, K. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem. Biophys. Res. Commun., 2004, 318(4), 1072-1078.
27. Deng, Y.; Bi, H.C.; Zhao, L.Z.; Wang, X.D.; Chen, J.; Ou, Z.M.; Ding, L.; Xu, L.J.; Guan, S.; Chen, X.; Zhou, S.F.; Huang, M. Induction of cytochrome P450 3A by the Ginkgo biloba extract and bilobalides in human and rat primary hepatocytes. Drug Metab. Lett., 2008, 2(1), 60-66.
28. Hellum, B.H.; Hu, Z.; Nilsen, O.G. Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes. Basic Clin. Pharmacol. Toxicol., 2009, 105(1), 58-63.
29. Zhao, X.D.; Dong, N.; Man, H.T.; Fu, Z.L.; Zhang, M.H.; Kou, S.; Ma, S.L. Antiproliferative effect of the Ginkgo biloba extract is associated with the enhancement of cytochrome P450 1B1 expression in estrogen receptor-negative breast cancer cells. Biomed. Rep., 2013, 1(5), 797-801.
30. Hiura, Y.; Satsu, H.; Hamada, M.; Shimizu, M. Analysis of flavonoids regulating the expression of UGT1A1 via xenobiotic receptors in intestinal epithelial cells. Biofactors, 2014, 40(3), 336-345.
31. Oliveira, E.J.; Watson, D.G. In vitro glucuronidation of kaempferol and quercetin by human UGT-1A9 microsomes. FEBS. Lett., 2000, 471(1), 1-6.
32. Wang, Y.; Cao, J.; Zeng, S. Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin. J. Pharm. Pharmacol., 2005, 57(6), 751-758.
33. An, G.; Gallegos, J.; Morris, M.E. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux. Drug Metab. Dispos., 2011, 39(3), 426-432.
34. Mandery, K.; Balk, B.; Bujok, K.; Schmidt, I.; Fromm, M.F.; Glaeser, H. Inhibition of hepatic uptake transporters by flavonoids. Eur. J. Pharm. Sci., 2012, 46(1-2), 79-85.
35. Fuchikami, H.; Satoh, H.; Tsujimoto, M.; Ohdo, S.; Ohtani, H.; Sawada, Y. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos., 2006, 34(4), 577-582.
36. Zhao, L.Z.; Huang, M.; Chen, J.; Ee, P.L.; Chan, E.; Duan, W.; Guan, Y.Y.; Hong, Y.H.; Chen, X.; Zhou, S. Induction of propranolol metabolism by Ginkgo biloba extract EGb 761 in rats. Curr. Drug Metab., 2006, 7(6), 577-587.
37. Deng, Y.; Bi, H.C.; Zhao, L.Z.; He, F.; Liu, Y.Q.; Yu, J.J.; Ou, Z.M.; Ding, L.; Chen, X.; Huang, Z.Y.; Huang, M.; Zhou, S.F. Induction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb 761 in rats. Xenobiotica, 2008, 38(5), 465-481.
38. Tang, J.; Sun, J.; Zhang, Y.; Li, L.; Cui, F.; He, Z. Herb-drug interactions: Effect of Ginkgo biloba extract on the pharmacokinetics of theophylline in rats. Food Chem. Toxicol., 2007, 45(12), 2441-2445.
39. Taki, Y.; Yokotani, K.; Yamada, S.; Shinozuka, K.; Kubota, Y.; Watanabe, Y.; Umegaki, K. Ginkgo biloba extract attenuates warfarin-mediated anticoagulation through induction of hepatic cytochrome P450 enzymes by bilobalide in mice. Phytomedicine, 2012, 19(2), 177-182.
40. Yoshioka, M.; Ohnishi, N.; Sone, N.; Egami, S.; Takara, K.; Yokoyama, T.; Kuroda, K. Studies on interactions between functional foods or dietary supplements and medicines. III. Effects of ginkgo biloba leaf extract on the pharmacokinetics of nifedipine in rats. Biol. Pharm. Bull., 2004, 27(12), 2042-2045.
41. Yang, C.Y.; Chao, P.D.; Hou, Y.C.; Tsai, S.Y.; Wen, K.C.; Hsiu, S.L. Marked decrease of cyclosporin bioavailability caused by coadministration of ginkgo and onion in rats. Food Chem. Toxicol., 2006, 44(9), 1572-1578.
42. Uchida, S.; Yamada, H.; Li, X.D.; Maruyama, S.; Ohmori, Y.; Oki, T.; Watanabe, H.; Umegaki, K.; Ohashi, K.; Yamada, S. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J. Clin. Pharmacol., 2006, 46(11), 1290-1298.
43. Markowitz, J.S.; Donovan, J.L.; Lindsay DeVane, C.; Sipkes, L.; Chavin, K.D. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J. Clin. Psychopharmacol., 2003, 23(6), 576-581.
44. Zadoyan, G.; Rokitta, D.; Klement, S.; Dienel, A.; Hoerr, R.; Gramatté, T.; Fuhr, U. Effect of Ginkgo biloba special extract EGb 761 on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur. J. Clin. Pharmacol., 2012, 68(5), 553-560.
45. Yin, O.Q.; Tomlinson, B.; Waye, M.M.; Chow, A.H.; Chow, M.S. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics, 2004, 14(12), 841-850.
46. Zuo, X.C.; Zhang, B.K.; Jia, S.J.; Liu, S.K.; Zhou, L.Y.; Li, J.; Zhang, J.; Dai, L.L.; Chen, B.M.; Yang, G.P.; Yuan, H. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur. J. Clin. Pharmacol., 2010, 66(5), 503-509.
47. Naccarato, M.; Yoong, D.; Gough, K. A potential drug-herbal interaction between Ginkgo biloba and efavirenz. J. Int. Assoc. Physicians AIDS Care (Chic), 2012, 11(2), 98-100.
48. Unger, M. Pharmacokinetic drug interactions involving Ginkgo biloba. Drug Metab. Rev., 2013, 45(3), 353-385.
49. von Moltke, L.L.; Weemhoff, J.L.; Bedir, E.; Khan, I.A.; Harmatz, J.S.; Goldman, P.; Greenblatt, D.J. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J. Pharm. Pharmacol., 2004, 56(8), 1039-1044.
50. Niemi, M.; Kivistö, K.T.; Hofmann, U.; Schwab, M.; Eichelbaum, M.; Fromm, M.F. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br. J. Clin. Pharmacol., 2005, 59, 602-604.
51. Tzvetkov, M.V.; Saadatmand, A.R.; Lötsch,, J.; Tegeder, I.; Stingl, J.C.; Brockmöller, J. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin. Pharmacol. Ther., 2009, 86, 299-306.
52. Robertson, S.M.; Davey, R.T.; Voell, J.; Formentini, E.; Alfaro, R.M.; Penzak, S.R. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr. Med. Res. Opin., 2008, 24(2), 591-599.
53. Fan, L.; Tao, G.Y.; Wang, G.; Chen, Y.; Zhang, W.; He, Y.J.; Li, Q.; Lei, H.P.; Jiang, F.; Hu, D.L.; Huang, Y.F.; Zhou, H.H. Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. Ann. Pharmacother., 2009, 43(5): 944-949.
54. Fan, L.; Mao, X.Q.; Tao, G.Y.; Wang, G.; Jiang, F.; Chen, Y.; Li, Q.; Zhang, W.; Lei, H.P.; Hu, D.L.; Huang, Y.F.; Wang, D.; Zhou, H.H. Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers. Xenobiotica., 2009, 39(3), 249-254.
55. Izzo, A.A.; Ernst, E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs, 2009, 69, 1777-1798.
56. Patel, J.; Buddha, B.; Dey, S.; Pal, D.; Mitra, A.K. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am. J. Ther., 2004, 11(4), 262-277.
57. Foster, B.C.; Vandenhoek, S.; Tang, R.; Budzinski, J.W.; Krantis, A.; Li, K.Y. Effect of several Chinese natural health products of human cytochrome P450 metabolism. J. Pharm. Pharm. Sci., 2002, 5(2), 185-189.
58. Ji, W.; Gong, B.Q. Hypolipidemic effects and mechanisms of Panax notoginseng on lipid profile in hyperlipidemic rats. J. Ethnopharmacol., 2007, 113, 318-324.
59. Kawase, A.; Yamada, A.; Gamou, Y.; Tahara, C.; Takeshita, F.; Murata, K.; Matsuda, H.; Samukawa, K.; Iwaki, M. Increased effects of ginsenosides on the expression of cholesterol 7-hydroxylase but not the bile salt export pump are involved in cholesterol metabolism. J. Nat. Med., 2013, 67(3), 545-553.
60. Stieger, B.; Meier, P.J. Bile salt transporters. Annu Rev. Physiol., 2002, 64, 635-661.
61. Kawase, A.; Yamada, A.; Gamou, Y.; Tahara, C.; Takeshita, F.; Murata, K.; Matsuda, H.; Samukawa, K.; Iwaki, M. Effects of ginsenosides on the expression of cytochrome P450s and transporters involved in cholesterol metabolism. J. Nat. Med., 2014, 68(2), 395-401.
62. Etheridge, A.S.; Black, S.R.; Patel, P.R.; So, J.; Mathews, J.M. An in vitro evaluation of cytochrome P450 inhibition and Pglycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med., 2007, 73, 731-741.
63. He, N.; Edeki, T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am. J. Ther., 2004, 11, 206-212.
64. Liu, Y.; Zhang, J.W.; Li, W.; Ma, H.; Sun, J.; Deng, M.C.; Yang, L. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci., 2006, 91, 356-64.
65. Chula, S.; Hang, L.; Yinying, B.; Jianning, S.; Shi, R. The effects of notoginsenoside R on the intestinal absorption of geniposide by the everted rat gut sac model. J. Ethnopharmacol., 2012, 142(1), 136-143.
66. Yang, Z.; Wang, J.R.; Niu, T.; Gao, S.; Yin, T.; You, M.; Jiang, Z.H.; Hu, M. Inhibition of P-glycoprotein leads to improved oral bioavailability of compound K, an anticancer metabolite of red ginseng extract produced by gut microflora. Drug Metab. Dispos., 2012, 40(8), 1538-1544.
67. Gurley, B.J.; Gardner, S.F.; Hubbard, M.A.; Williams, D.K.; Gentry, W.B.; Cui, Y.; Ang, C.Y. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging, 2005, 22(6), 525-539.
68. Malati, C.Y.; Robertson, S.M.; Hunt, J.D.; Chairez, C.; Alfaro, R.M.; Kovacs, J.A.; Penzak, S.R. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. J. Clin. Pharmacol., 2012, 52(6), 932-939.
69. Iciek, M.; Kwiecien, I.; Wlodek, L. Biological properties of garlic and garlic-derived organosulfur compounds. Environ. Mol. Mutagen, 2009, 50(3), 247-265.
70. Foster, B.C.; Foster, M.S.; Vandenhoek, S.; Krantis, A.; Budzinski, J.W.; Arnason, J.T.; Gallicano, K.D.; Choudri, S. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J. Pharm. Pharm. Sci., 2001, 4(2), 176-184.
71. Zhang, P.; Noordine, M.L.; Cherbuy, C.; Vaugelade, P.; Pascussi, J.M.; Duée, P.H.; Thomas, M. Different activation patterns of rat xenobiotic metabolism genes by two constituents of garlic. Carcinogenesis, 2006, 27, 2090-2095.
72. Müller, A.C.; Kanfer, I. Potential pharmacokinetic interactions between antiretrovirals and medicinal plants used as complementary and African traditional medicines. Biopharm. Drug Dispos., 2011, 32(8), 458-470.
73. Mohamed, M.E.; Frye, R.F. Inhibitory effects of commonly used herbal extracts on UDP-glucuronosyltransferase 1A4, 1A6, and 1A9 enzyme activities. Drug Metab. Dispos., 2011, 39(9), 1522-1528.
74. Berginc, K.; Zakelj, S.; Ursic, D.; Kristl, A. Aged garlic extract stimulates p-glycoprotein and multidrug resistance associated protein 2 mediated effluxes. Biol. Pharm. Bull., 2009, 32(4), 694-699.
75. Berginc, K.; Kristl, A. The mechanisms responsible for garlic-drug interactions and their in vivo relevance. Curr. Drug Metab., 2013, 14(1), 90-101.
76. Arora, A.; Seth, K.; Shukla, Y. Reversal of P-glycoproteinmediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver. Carcinogenesis, 2004, 25(6), 941-949.
77. Demeule, M.; Brossard, M.; Turcotte, S.; Regina, A.; Jodoin, J.; Béliveau, R. Diallyl disulfide, a chemopreventive agent in garlic, induces multidrug resistance- Associated protein 2 expression. Biochem. Biophys. Res. Commun., 2004, 324(2), 937-945.
78. Xia, Q.; Wang, Z.Y.; Li, H.Q.; Diao, Y.T.; Li, X.L.; Cui, J.; Chen, X.L.; Li, H. Reversion of p-glycoprotein-mediated multidrug resistance in human leukemic cell line by diallyl trisulfide. Evid. Based Complement Alternat. Med., 2012, 2012, 719805.
79. Hong, J.Y.; Smith, T.; Lee, M.J.; Li, W.S.; Ma, B.L.; Ning, S.M.; Brady, J.F.; Thomas, P.E.; Yang, C.S. Metabolism of carcinogenic nitrosamines by rat nasal mucosa and the effect of diallyl sulfide. Cancer Res., 1991, 51(5), 1509-1514.
80. Reddy, G.D.; Reddy, A.G.; Rao, G.S.; Kumar, M.V. Pharmacokinetic interaction of garlic and atorvastatin in dyslipidemic rats. Indian J. Pharmacol., 2012, 44(2), 246-252.
81. Le Bon, A.M.; Vernevaut, M.F.; Guenot, L.; Kahane, R.; Auger, J.; Arnault, I.; Haffner, T.; Siess, M.H. Effects of garlic powders with varying alliin contents on hepatic drug metabolizing enzymes in rats. J. Agric. Food Chem., 2003, 51(26), 7617-7623.
82. Morris, C.R.; Chen, S.C.; Zhou, L.; Schopfer, L.M.; Ding, X.; Mirvish, S.S. Inhibition by allyl sulfides and phenethyl isothiocyanate of methyl-n-pentylnitrosamine depentylation by rat esophageal microsomes, human, and rat CYP2E1, and rat CYP2A3. Nutr. Cancer, 2004, 48, 54-63.
83. Markowitz, J.S.; Devane, C.L.; Chavin, K.D.; Taylor, R.M.; Ruan, Y.; Donovan, J.L. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin. Pharmacol. Ther., 2003, 74(2), 170-177.
84. Piscitelli, S.C.; Burstein, A.H.; Welden, N.; Gallicano, K.D.; Falloon, J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin. Infect. Dis., 2002, 34, 234-238.
85. Loizou, G.D.; Crocker, J. The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: a phenotyping study using chlorzoxazone. Hum. Exp. Toxicol., 2001, 20, 321-327.
86. Hajda, J.; Rentsch, K.M.; Gubler, C.; Steinert, H.; Stieger, B.; Fattinger, K. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur. J. Pharm. Sci., 2010, 41(5), 729-735.
87. Wuttke, W.; Jarry, H.; Haunschild, J.; Stecher, G.; Schuh, M.; Seidlova-Wuttke, D. The non-estrogenic alternative for the treatment of climacteric complaints: Black cohosh (Cimicifuga or Actaea racemosa). J. Steroid Biochem. Mol. Biol., 2014, 139, 302-310.
88. Geller, S.E.; Studee, L. Botanical and dietary supplements for mood and anxiety in menopausal women. Menopause, 2007, 14(3 Pt 1), 541-549.
89. Huang, Y.; Jiang, B.; Nuntanakorn, P.; Kennelly, E.J.; Shord, S.; Lawal, T.O.; Mahady, G.B. Fukinolic acid derivatives and triterpene glycosides from black cohosh inhibit CYP isozymes, but are not cytotoxic to Hep-G2 cells in vitro. Curr. Drug Saf., 2010, 5(2), 118-124.
90. Sevior, D.K.; Hokkanen, J.; Tolonen, A.; Abass, K.; Tursas, L.; Pelkonen, O.; Ahokas, J.T. Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail. Xenobiotica, 2010, 40, 245-254.
91. Tamaki, H.; Satoh, H.; Hori, S.; Ohtani, H.; Sawada, Y. Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids. Drug Metab. Pharmacokinet., 2010, 25(2), 170-179.
92. Pang, X.; Cheng, J.; Krausz, K.W.; Guo, D.A.; Gonzalez, F.J. Pregnane X receptor-mediated induction of Cyp3a by black cohosh. Xenobiotica, 2011, 41(2), 112-123.
93. Gurley, B.J.; Barone, G.W.; Williams, D.K.; Carrier, J.; Breen, P.; Yates, C.R.; Song, P.; Hubbard, M.A.; Tong, Y.; Cheboyina, S. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab. Dispos., 2006, 34, 69-74.
94. Gurley, B.; Hubbard M.A.; Williams, D.K.; Thaden, J.; Tong, Y.; Gentry, W.B.; Breen, P.; Carrier, D.J.; Cheboyina, S. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J. Clin. Pharmacol, 2006, 46, 201-213.
95. Gurley, B.J.; Gardner, S.F.; Hubbard, M.A.; Williams, D.K.; Gentry, W.B.; Khan, I.A.; Shah, A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin. Pharmacol. Ther., 2005, 77, 415-426.
96. Gurley, B.J.; Swain, A.; Hubbard, M.A.; Williams, D.K.; Barone, G.; Hartsfield, F.; Tong, Y.; Carrier, D.J.; Cheboyina, S.; Battu, S.K. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol. Nutr. Food Res., 2008, 52(7), 755-763.
97. Yu, D.; Yuan, Y.; Jiang, L.; Tai, Y.; Yang, X.; Hu, F.; Xie, Z. Antiinflammatory effects of essential oil in Echinacea purpurea L. Pak. J. Pharm. Sci., 2013, 26(2), 403-408.
98. Di Pierro, F.; Rapacioli, G.; Ferrara, T.; Togni, S. Use of a standardized extract from Echinacea angustifolia (Polinacea) for the prevention of respiratory tract infections. Altern. Med. Rev., 2012, 17(1), 36-41.
99. Hellum, B.H.; Nilsen, O.G. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin. Pharmacol. Toxicol., 2008, 102(5), 466-475.
100. Romiti, N.; Pellati, F.; Nieri, P.; Benvenuti, S.; Adinolfi, B.; Chieli, E. P-Glycoprotein inhibitory activity of lipophilic constituents of Echinacea pallida roots in a human proximal tubular cell line. Planta Med., 2008, 74(3), 264-266.
101. Hansen, T.S.; Nilsen, O.G. Echinacea purpurea and P-glycoprotein drug transport in Caco-2 cells. Phytother Res., 2009, 23(1), 86-91.
102. Qiang, Z.; Hauck, C.; McCoy, J.A.; Widrlechner, M.P.; Reddy, M.B.; Murphy, P.A.; Hendrich, S. Echinacea sanguinea and Echinacea pallida extracts stimulate glucuronidation and basolateral transfer of Bauer alkamides 8 and 10 and ketone 24 and inhibit Pglycoprotein transporter in Caco-2 cells. Planta Med., 2013, 79(3-4), 266-274.
103. Mrozikiewicz, P.M.; Bogacz, A.; Karasiewicz, M.; Mikolajczak, P.L.; Ozarowski, M.; Seremak-Mrozikiewicz, A.; Czerny, B.; Bobkiewicz-Kozlowska, T.; Grzeskowiak, E. The effect of standardized Echinacea purpurea extract on rat cytochrome P450 expression level. Phytomedicine, 2010, 17(10), 830-833.
104. Penzak, S.R.; Robertson, S.M.; Hunt, J.D.; Chairez, C.; Malati, C.Y.; Alfaro, R.M.; Stevenson, J.M.; Kovacs, J.A. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy, 2010, 30(8), 797-805.
105. Gorski, J.C.; Huang, S.M.; Pinto, A.; Hamman, M.A.; Hilligoss, J.K.; Zaheer, N.A.; Desai, M.; Miller, M.; Hall, S.D. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin. Pharmacol. Ther., 2004, 75(1), 89-100.
106. Gurley, B.J.; Swain, A.; Williams, D.K.; Barone, G.; Battu, S.K. Gauging the clinical significance of P-glycoprotein-mediated herbdrug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol. Nutr. Food Res., 2008, 52(7), 772-779.
107. Xiao, J.; Fai So, K.; Liong, E.C.; Tipoe, G.L. Recent Advances in the Herbal Treatment of Non-Alcoholic Fatty Liver Disease. J. Tradit. Complement Med., 2013, 3(2), 88-94.
108. Hackett, E.S.; Twedt, D.C.; Gustafson, D.L. Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease. J. Vet. Intern. Med., 2013, 27(1), 10-16.
109. Mohd Fozi, N.F.; Mazlan, M.; Shuid, A.N.; Isa Naina, M. Milk thistle: a future potential anti-osteoporotic and fracture healing agent. Curr. Drug Targets, 2013, 14(14), 1659-1666.
110. Budzinski, J.W.; Trudeau, V.L.; Drouin, C.E.; Panahi, M.; Arnason, J.T.; Foster, B.C. Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products. Can. J. Physiol. Pharmacol., 2007, 85(9), 966-978.
111. Mohamed, M.E.; Frye, R.F. Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies. Planta Med., 2011, 77(4), 311-321.
112. Zuber, R.; Modriansk, M.; Dvorák, Z.; Rohovsk, P.; Ulrichová, J.; Simánek, V.; Anzenbacher, P. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother. Res., 2002, 16(7), 632-638.
113. Venkataramanan, R.; Ramachandran, V.; Komoroski, B.J.; Zhang, S.; Schiff, P.L.; Strom, S.C. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab. Dispos., 2000, 28(11), 1270-1273.
114. Sridar, C.; Goosen, T.C.; Kent, U.M.; Williams, J.A.; Hollenberg, P.F. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab. Dispos., 2004, 32(6), 587-594.
115. Doehmer, J.; Tewes, B.; Klein, K.U.; Gritzko, K.; Muschick, H.; Mengs, U. Assessment of drug-drug interaction for silymarin. Toxicol. In vitro, 2008, 22 (3), 610-617
116. Doehmer, J.; Weiss, G.; McGregor, G.P.; Appel, K. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities. Toxicol. In vitro, 2011, 25(1), 21-27.
117. Li, C.; Lee, M.Y.; Choi, J.S. Effects of silybinin, CYP3A4 and Pglycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats. Pharmazie, 2010, 65(7), 510-514.
118. Gurley, B.J.; Gardner, S.F.; Hubbard, M.A.; Williams, D.K.; Gentry, W.B.; Carrier, J.; Khan, I.A.; Edwards, D.J.; Shah, A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin. Pharmacol. Ther., 2004, 76(5), 428-440.
119. DiCenzo, R.; Shelton, M.; Jordan, K.; Koval, C.; Forrest, A.; Reichman, R.; Morse, G. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy, 2003, 23(7), 866-870.
120. van Erp, N.P.; Baker, S.D.; Zhao, M.; Rudek, M.A.; Guchelaar, H.J.; Nortier, J.W.; Sparreboom, A.; Gelderblom, H. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin. Cancer Res., 2005, 11(21), 7800-7806.
121. Fuhr, U.; Beckmann-Knopp, S.; Jetter, A.; Lück, H.; Mengs, U. The effect of silymarin on oral nifedipine pharmacokinetics. Planta. Med., 2007, 73(14), 1429-1435.
122. Han, Y.; Guo, D.; Chen, Y.; Chen, Y.; Tan, Z.R.; Zhou, H.H. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. ,Eur J. Clin. Pharmacol., 2009, 65(6), 585-591.
123. Rajnarayana, K.; Reddy, M.S.; Vidyasagar, J.; Krishna, D.R. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung., 2004, 54(2), 109-113.
124. Han, Y.; Guo, D.; Chen, Y.; Tan, Z.R.; Zhou, H.H. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. Xenobiotica, 2009, 39(9), 694-699.
125. Gounder, R. Kava consumption and its health effects. Pac Health Dialog., 2006, 13(2), 131-135.
126. Teschke, R.; Lebot, V. Proposal for a kava quality standardization code. Food Chem. Toxicol., 2011, 49(10), 2503-2516.
127. Owens, C.; Baergen, R.; Puckett, D. Online sources of herbal product information. Am. J. Med., 2014, 127(2), 109-115.
128. Li, Y.; Mei, H.; Wu, Q.; Zhang, S.; Fang, J.L.; Shi, L.; Guo, L. Methysticin and 7,8-dihydromethysticin are two major kavalactones in kava extract to induce CYP1A1. Toxicol. Sci., 2011, 124(2), 388-399.
129. Li, X.Z.; Ramzan, I. Role of ethanol in kava hepatotoxicity. Phytother. Res., 2010, 24(4), 475-480.
130. Mathews, J.M.; Etheridge, A.S.; Black, S.R. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab. Dispos., 2002, 30(11), 1153-1157.
131. Mathews, J.M.; Etheridge, A.S.; Valentine, J.L.; Black, S.R.; Coleman, D.P.; Patel, P.; So, J.; Burka, L.T. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab. Dispos., 2005, 33(10), 1555-1563.
132. Zou, L.; Henderson, G.L.; Harkey, M.R.; Sakai, Y.; Li, A. Effects of kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Phytomedicine, 2004, 11(4), 285-294.
133. Unger, M.; Holzgrabe, U.; Jacobsen, W.; Cummins, C.; Benet, L.Z. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta. Med., 2002, 68(12), 1055-1058.
134. Unger, M.; Frank, A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun. Mass Spectrom, 2004, 18(19), 2273-2281.
135. Weiss, J.; Sauer, A.; Frank, A.; Unger, M. Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit Pglycoprotein in vitro. Drug Metab. Dispos., 2005, 33(11), 1580-1583.
136. Lim, S.T.; Dragull, K.; Tang, C.S.; Bittenbender, H.C.; Efird, J.T.; Nerurkar, P.V. Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicol. Sci., 2007, 97(1), 214-221.
137. Yamazaki, Y.; Hashida, H.; Arita, A.; Hamaguchi, K.; Shimura, F. High dose of commercial products of kava (Piper methysticum) markedly enhanced hepatic cytochrome P450 1A1 mRNA expression with liver enlargement in rats. Food Chem, Toxicol., 2008, 46(12), 3732-3738.
138. Gurley, B.J.; Swain, A.; Hubbard, M.A.; Hartsfield, F.; Thaden, J.; Williams, D.K.; Gentry, W.B.; Tong, Y. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin. Pharmacol. Ther., 2008, 83(1), 61-69.
139. Gurley, B.J.; Swain, A.; Barone, G.W.; Williams, D.K.; Breen, P.; Yates, C.R.; Stuart, L.B.; Hubbard, M.A.; Tong, Y.; Cheboyina, S. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab, Dispos., 2007, 35(2), 240-245.
140. Sienkiewicz, J.; Czarnik-Matusewicz, H.; Wiela-Hojeska, A. Phytotherapy threats with emphasis on St. John's wort medicines. Pol. Merkur Lekarski., 2013, 35(209), 309-312.
141. Wölfle, U.; Seelinger, G.; Schempp, C.M. Topical application of St. John's wort (Hypericum perforatum). Planta Med., 2014, 80(2-3), 109-120.
142. Huang, L.F.; Wang, Z.H.; Chen, S.L. Hypericin: chemical synthesis and biosynthesis. Chin. J. Nat. Med., 2014, 12(2), 81-88.
143. Hokkanen, J.; Tolonen, A.; Mattila, S.; Turpeinen, M. Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur. J. Pharm. Sci., 2011, 42(3), 273-284.
144. Kober, M.; Pohl, K.; Efferth, T. Molecular mechanisms underlying St. John's wort drug interactions. Curr. Drug Metab., 2008, 9(10), 1027-1037.
145. Xu, H.; Williams, K.M.; Liauw, W.S.; Murray, M.; Day, R.O.; McLachlan, A.J. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br. J. Pharmacol., 2008, 153(7), 1579-1586.
146. Wang, L.S.; Zhu, B.; Abd El-Aty, A.M.; Zhou, G.; Li, Z.; Wu, J.; Chen, G.L.; Liu, J.; Tang, Z.R.; An, W.; Li, Q.; Wang, D.; Zhou, H.H. The influence of St John's Wort on CYP2C19 activity with respect to genotype. J. Clin. Pharmacol., 2004, 44(6), 577-5781.
147. Hellum, B.H.; Nilsen, O.G. The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol. Basic Clin. Pharmacol. Toxicol., 2007, 101(5), 350-358.
148. Obach, R.S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J. Pharmacol. Exp. Ther., 2000, 294(1), 88-95.
149. Chaudhary, A.; Willett, K.L. Inhibition of human cytochrome CYP 1 enzymes by flavonoids of St. John's wort. Toxicology, 2006, 217(2-3), 194-205.
150. Lee, J.Y.; Duke, R.K.; Tran, V.H.; Hook, J.M.; Duke, C.C. Hyperforin and its analogues inhibit CYP3A4 enzyme activity. Phytochemistry, 2006, 67(23), 2550-2560.
151. Moore, L.B.; Goodwin, B.; Jones, S.A.; Wisely, G.B.; Serabjit-Singh, C.J.; Willson, T.M.; Collins, J.L.; Kliewer, S.A. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad Sci. U S A., 2000, 97(13), 7500-7502.
152. Gutmann, H.; Poller, B.; Büter, K.B.; Pfrunder, A.; Schaffner, W.; Drewe, J. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression? Planta. Med., 2006, 72(8), 685-690.
153. Hansen, T.S.; Nilsen, O.G. In vitro CYP3A4 metabolism: inhibition by Echinacea purpurea and choice of substrate for the evaluation of herbal inhibition. Basic Clin. Pharmacol. Toxicol., 2008, 103(5), 445-449.
154. Komoroski, B.J.; Parise, R.A.; Egorin, M.J.; Strom, S.C.; Venkataramanan, R. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Clin. Cancer Res., 2005, 11(19 Pt 1), 6972-6979.
155. Komoroski, B.J.; Zhang, S.; Cai, H.; Hutzler, J.M.; Frye, R.; Tracy, T.S.; Strom, S.C.; Lehmann, T.; Ang, C,Y.; Cui, Y.Y.; Venkataramanan, R. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab. Dispos., 2004, 32(5), 512-518.
156. Weber, C.C.; Kressmann, S.; Fricker, G.; Müller, W.E. Modulation of P-glycoprotein function by St John's wort extract and its major constituents. Pharmacopsychiatry, 2004, 37(6), 292-298.
157. Tian, R.; Koyabu, N.; Morimoto, S.; Shoyama, Y.; Ohtani, H.; Sawada, Y. Functional induction and de-induction of Pglycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line. Drug Metab. Dispos., 2005, 33(4), 547-554.
158. Bray, B.J.; Perry, N.B.; Menkes, D.B.; Rosengren, R.J. St. John's wort extract induces CYP3A and CYP2E1 in the Swiss Webster mouse. Toxicol. Sci., 2002, 66(1), 27-33.
159. Dürr, D.; Stieger, B.; Kullak-Ublick, G.A.; Rentsch, K.M.; Steinert, H.C.; Meier, P.J.; Fattinger, K. St John's Wort induces intestinal P glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther., 2000, 68(6), 598-604.
160. Dostalek, M.; Pistovcakova, J.; Jurica, J.; Tomandl, J.; Linhart, I.; Sulcová, A.; Hadasova, E. Effect of St John's wort (Hypericum perforatum) on cytochrome P-450 activity in perfused rat liver. Life Sci., 2005, 78(3), 239-244.
161. Cantoni, L.; Rozio, M.; Mangolini, A.; Hauri, L.; Caccia, S. Hyperforin contributes to the hepatic CYP3A-inducing effect of Hypericum perforatum extract in the mouse. Toxicol. Sci., 2003, 75(1), 25-30.
162. Garrovo, C.; Rosati, A.; Bartoli, F.; Decorti, G. St John's wort modulation and developmental expression of multidrug transporters in the rat. Phytother. Res., 2006, 20(6), 468-473.
163. Rengelshausen, J.; Banfield, M.; Riedel, K.D.; Burhenne, J.; Weiss, J.; Thomsen, T.; Walter-Sack, I.; Haefeli, W.E.; Mikus, G. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin. Pharmacol. Ther., 2005, 78(1), 25-33.
164. Goey, A.K.; Mooiman, K.D.; Beijnen, J.H.; Schellens, J.H.; Meijerman, I. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treat Rev., 2013, 39(7), 773-783.
165. Imai, H.; Kotegawa, T.; Tsutsumi, K.; Morimoto, T.; Eshima, N.; Nakano, S.; Ohashi, K. The recovery time-course of CYP3A after induction by St John's wort administration. Br. J. Clin. Pharmacol., 2008, 65(5), 701-707.
166. Johne, A.; Schmider, J.; Brockmöller, J.; Stadelmann, A.M.; Störmer, E.; Bauer, S.; Scholler, G.; Langheinrich, M.; Roots, I. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort ( Hypericum perforatum ). J. Clin. Psychopharmacol., 2002, 22(1), 46-54.
167. Holtzman, C.W.; Wiggins, B.S.; Spinler, S.A. Role of Pglycoprotein in statin drug interactions. Pharmacotherapy, 2006, 26(11), 1601-1607.
168. Alscher, D.M.; Klotz, U. Drug interaction of herbal tea containing St. John's wort with cyclosporine. Transpl. Int., 2003, 16(7), 543-544.
169. Goey, A.K.; Meijerman, I.; Rosing, H.; Marchetti, S.; Mergui-Roelvink, M.; Keessen, M.; Burgers, J.A.; Beijnen, J.H.; Schellens, J.H. The effect of St John's wort on the pharmacokinetics of docetaxel. Clin. Pharmacokinet., 2014, 53(1), 103-110.
170. Lundahl, A.; Hedeland, M.; Bondesson, U.; Knutson, L.; Lennernäs, H. The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. Eur. J. Pharm. Sci., 2009, 36(4-5), 433-443.
171. Miller, J.L. Interaction between indinavir and St. John's wort reported. Am. J. Health Syst. Pharm., 2000, 57(7), 625-626.
172. Eich-Höchli, D.; Oppliger, R.; Golay, K.P.; Baumann, P.; Eap, C.B. Methadone maintenance treatment and St. John's Wort- A case report. Pharmacopsychiatry, 2003, 36(1), 35-37.
173. Qi, J.W.; Nakamura, K.; Hosokawa, S.; Okada, Y.; Horiuchi, R.; Yamamoto, K. Time-dependent induction of midazolam-1-hydroxylation enzymes in rats treated with St. John's wort. Biol. Pharm. Bull., 2005, 28(8), 1467-1471.
174. de Maat, M.M.; Hoetelmans, R.M.; Math, t R.A.; van Gorp, E.C.; Meenhorst, P.L.; Mulder, J.W.; Beijnen, J.H. Drug interaction between St John's wort and nevirapine. AIDS, 2001, 15(3), 420-421.
175. Jiang, X.; Williams, K.M.; Liauw, W.S.; Ammit, A.J.; Roufogalis, B.D.; Duke, C.C.; Day, R.O.; McLachlan, A.J. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br. J. Clin. Pharmacol., 2004, 57(5), 592-599.
176. Wang, X.D.; Li, J.L.; Lu, Y.; Chen, X.; Huang, M.; Chowbay, B.; Zhou, S.F. Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatographytandem mass spectrometry: Application to a clinical herb-drug interaction study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 852(1-2), 534-544.
177. Hafner, V.; Jäger, M.; Matthée, A.K.; Ding, R.; Burhenne, J.; Haefeli, W.E.; Mikus, G. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity. Clin. Pharmacol. Ther., 2010, 87(2), 191-196.
178. Borrelli, F.; Izzo, A.A. Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. AAPS. J., 2009, 11(4), 710-727.
179. Kawaguchi, A.; Ohmori, M.; Tsuruoka, S.; Nishiki, K.; Harada, K.; Miyamori, I.; Yano, R.; Nakamura, T.; Masada, M.; Fujimura, A. Drug interaction between St John's Wort and quazepam. Br. J. Clin. Pharmacol., 2004, 58(4), 403-410.
180. Lei, H.P.; Yu, X.Y.; Xie, H.T.; Li, H.H.; Fan, L.; Dai, L.L.; Chen, Y.; Zhou, H.H. Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers. Xenobiotica, 2010, 40(4), 275-281.
181. Schwarz, U.I.; Hanso, H.; Oertel, R.; Miehlke, S.; Kuhlisch, E.; Glaeser, H.; Hitzl, M.; Dresser, G.K.; Kim, R.B.; Kirch, W. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin. Pharmacol. Ther., 2007, 81(5), 669-678.
182. Johne, A.; Perloff, E.S.; Bauer, S.; Schmider, J.; Mai, I.; Brockmöller, J.; Roots, I. Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. Eur. J. Clin. Pharmacol., 2004, 60(9),617-622.
183. Dresser, G.K.; Schwarz, U.I.; Wilkinson, G.R.; Kim, R.B. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin. Pharmacol. Ther.,. 2003, 73(1), 41-50.
184. Mai, I.; Bauer, S.; Perloff, E.S.; Johne, A.; Uehleke, B.; Frank, B.; Budde, K.; Roots, I. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin. Pharmacol. Ther., 2004, 76(4), 330-340.
185. Alscher, D.M.; Klotz, U. Drug interaction of herbal tea containing St. John's wort with cyclosporine. Transpl. Int., 2003, 16(7), 543-544.
186. Mueller, S.C.; Uehleke, B.; Woehling, H.; Petzsch, M.; Majcher-Peszynska, J.; Hehl, E.M.; Sievers, H.; Frank, B.; Riethling, A.K.; Drewelow, B. Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin. Clin. Pharmacol. Ther., 2004, 75(6), 546-557.
187. Wang, Z.; Hamman, M.A.; Huang, S.M.; Lesko, L.J.; Hall, S.D. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin. Pharmacol. Ther., 2002, 71(6), 414-420.
188. Smith, P.F.; Bullock, J.M.; Booker, B.M.; Haas, C.E.; Berenson, C.S.; Jusko, W.J. Induction of imatinib metabolism by hypericum perforatum. Blood, 2004, 104(4), 1229-1230.
189. Frye, R.F.; Fitzgerald, S.M.; Lagattuta, T.F.; Hruska, M.W.; Egorin, M.J. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin. Pharmacol. Ther., 2004, 76(4), 323-329.
190. Portolés, A.; Terleira, A.; Calvo, A.; Martínez, I.; Resplandy, G. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. J. Clin. Pharmacol., 2006, 46(10), 1188-1194.
191. Wang, L.S.; Zhu, B.; Abd El-Aty, A.M.; Zhou, G.; Li, Z.; Wu, J.; Chen, G.L.; Liu, J.; Tang, Z.R.; An, W.; Li, Q.; Wang, D.; Zhou, H.H. The influence of St John's Wort on CYP2C19 activity with respect to genotype. J. Clin. Pharmacol., 2004, 44(6), 577-581.
192. Jiang, X.; Williams, K.M.; Liauw, W.S.; Ammit, A.J.; Roufogalis, B.D.; Duke, C.C.; Day, R.O.; McLachlan, A.J. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br. J. Clin. Pharmacol., 2004, 57(5), 592-599.
193. Jain, S.; Yadav, P.P.; Gill, V.; Vasudeva, N.; Singla, N. Terminalia arjuna a sacred medicinal plant: Phytochemical and pharmacological profile. Phytochem Rev., 2009, 8, 491-502.
194. Aneja, K.R.; Sharma, C.; Joshi, R. Antimicrobial activity of Terminalia arjuna Wight & Arn.: an ethnomedicinal plant against pathogens causing ear infection. Braz. J. Otorhinolaryngol., 2012, 78(1), 68-74.
195. Dwivedi, S. Terminalia arjuna Wight & Arn.- A useful drug for cardiovascular disorders. J. Ethnopharmacol., 2007, 114(2), 114-129.
196. Varghese, A.; Pandita, N.; Gaud, R.S. In vitro and in vivo Evaluation of CYP1A Interaction Potential of Terminalia Arjuna Bark. Indian J. Pharm. Sci., 2014, 76(2), 138-147.
197. Whiterock, V.J.; Morgan, D.G.; Lentz, K.A.; Orcutt, T.L.; Sinz, M.W. Phenacetin pharmacokinetics in CYP1A2-deficient beagle dogs. Drug Metab. Dispos., 2012, 40(2), 228-231.
198. Venkataramanan, R.; Komoroski, B.; Strom, S. In vitro and in vivo assessment of herb drug interactions. Life Sci., 2006, 78(18), 2105-2115.
199. Markowitz, J.S.; von Moltke, L.L.; Donovan, J.L. Predicting interactions between conventional medications and botanical products on the basis of in vitro investigations. Mol. Nutr. Food Res., 2008, 52(7), 747-754.
200. Markowitz, J.S.; Donovan, J.L.; DeVane, C.L.; Taylor, R.M.; Ruan, Y.; Wang, J.S.; Chavin, K.D. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA, 2003, 290(11), 1500-1504.